Cardiovascular Surgery

This channel includes news and new technology innovations for cardiac surgery. This includes coronary bypass grafts, surgical valve replacements.

Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018

November 2, 2018 — Hospitals that routinely perform a...

LivaNova Warns of Potential Infection Risks With 3T Heater-Cooler Systems
News | Cardiovascular Surgery | October 25, 2018

October 25, 2018 — On Oct. 18, 2018, LivaNova issued a...

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018

October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U....

Two of the top videos in September both had to do with interventional cardiology hemodynamic support support protocols. The top piece of content in September is an interview on the protocols used to determine what device technology to use at Henry Ford Hospital in Detroit. Number 13 on the list is another video on late-breaking data presented TCT 2018 from the National Cardiogenic Shock Initiative (NCSI) where mortality was improved by 50 percent over the current standard of care. Pictured here are Abiomed

Two of the top videos in September both had to do with interventional cardiology hemodynamic support protocols. The top piece of content in September is an interview on the protocols used to determine what device technology to use at Henry Ford Hospital in Detroit. No. 13 on the list is another video on late-breaking data presented at TCT 2018 from the National Cardiogenic Shock Initiative (NCSI) where mortality was improved by 50 percent over the current standard of care. Pictured here are Abiomed Impella percutaneous ventricular assist devices, which are mentioned prominently in both videos. 

Feature | October 01, 2018 | Dave Fornell, Editor

October 1, 2018 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC...

St. Louis Children's and Washington University Heart Center Perform Rare Infant Heart-Lung Transplant

Image courtesy of St. Louis Children's and Washington University Heart Center

News | Congenital Heart | September 25, 2018

September 25, 2018 — Five-month-old Jack Palmer is home with his family in Kansas City after undergoing an extremely...

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018

September 6, 2018 — While it is firmly established that the use of one internal thoracic artery can improve life...

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018

July 26, 2018 — The number of patients undergoing...

Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018

May 23, 2018 — Abbott has initiated a Class I recall of the HeartMate 3...

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first...

LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China
News | Heart Valve Technology | March 30, 2018

March 30, 2018 — LivaNova PLC announced the first patient enrollment in the Perceval Valve...

Contrast-Free Cardiac MRI May Better Assess Need for Mitral Valve Surgery
News | Magnetic Resonance Imaging (MRI) | February 27, 2018

February 27, 2018 – A new study published in the Journal of the American College of Cardiology confirms non-invasive...

AtriCure Launches AtriClip FLEX•V Device in the United States
Technology | Left Atrial Appendage (LAA) Occluders | February 22, 2018

February 22, 2018 — AtriCure Inc. announced that it has launched the AtriClip FLEX•V...

Technavio Market Study Shows Donor Shortage and Improved Survival Rate
News | Hemodynamic Support Devices | January 25, 2018

January 25, 2018 – According to the latest market study released by Technavio, the global circulatory support...

Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018

January 17, 2018 — Secant Group, in partnership with its sister company SanaVita Medical, announced new technology...

Overlay Init